Cargando…
Tumor response from durvalumab (MEDI4736) + tremelimumab treatment in patients with advanced non-small cell lung cancer (NSCLC) is observed regardless of PD-L1 status
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2015
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4649434/ http://dx.doi.org/10.1186/2051-1426-3-S2-P193 |
| _version_ | 1782401357699874816 |
|---|---|
| author | Rizvi, Naiyer Chaft, Jamie Balmanoukian, Ani Goldberg, Sarah B Sanborn, Rachel E Steele, Keith E Rebelatto, Marlon C Gu, Yu Karakunnel, Joyson J Antonia, Scott |
| author_facet | Rizvi, Naiyer Chaft, Jamie Balmanoukian, Ani Goldberg, Sarah B Sanborn, Rachel E Steele, Keith E Rebelatto, Marlon C Gu, Yu Karakunnel, Joyson J Antonia, Scott |
| author_sort | Rizvi, Naiyer |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-4649434 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2015 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-46494342015-11-24 Tumor response from durvalumab (MEDI4736) + tremelimumab treatment in patients with advanced non-small cell lung cancer (NSCLC) is observed regardless of PD-L1 status Rizvi, Naiyer Chaft, Jamie Balmanoukian, Ani Goldberg, Sarah B Sanborn, Rachel E Steele, Keith E Rebelatto, Marlon C Gu, Yu Karakunnel, Joyson J Antonia, Scott J Immunother Cancer Poster Presentation BioMed Central 2015-11-04 /pmc/articles/PMC4649434/ http://dx.doi.org/10.1186/2051-1426-3-S2-P193 Text en Copyright © 2015 Rizvi et al http://creativecommons.org/licenses/by/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
| spellingShingle | Poster Presentation Rizvi, Naiyer Chaft, Jamie Balmanoukian, Ani Goldberg, Sarah B Sanborn, Rachel E Steele, Keith E Rebelatto, Marlon C Gu, Yu Karakunnel, Joyson J Antonia, Scott Tumor response from durvalumab (MEDI4736) + tremelimumab treatment in patients with advanced non-small cell lung cancer (NSCLC) is observed regardless of PD-L1 status |
| title | Tumor response from durvalumab (MEDI4736) + tremelimumab treatment in patients with advanced non-small cell lung cancer (NSCLC) is observed regardless of PD-L1 status |
| title_full | Tumor response from durvalumab (MEDI4736) + tremelimumab treatment in patients with advanced non-small cell lung cancer (NSCLC) is observed regardless of PD-L1 status |
| title_fullStr | Tumor response from durvalumab (MEDI4736) + tremelimumab treatment in patients with advanced non-small cell lung cancer (NSCLC) is observed regardless of PD-L1 status |
| title_full_unstemmed | Tumor response from durvalumab (MEDI4736) + tremelimumab treatment in patients with advanced non-small cell lung cancer (NSCLC) is observed regardless of PD-L1 status |
| title_short | Tumor response from durvalumab (MEDI4736) + tremelimumab treatment in patients with advanced non-small cell lung cancer (NSCLC) is observed regardless of PD-L1 status |
| title_sort | tumor response from durvalumab (medi4736) + tremelimumab treatment in patients with advanced non-small cell lung cancer (nsclc) is observed regardless of pd-l1 status |
| topic | Poster Presentation |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4649434/ http://dx.doi.org/10.1186/2051-1426-3-S2-P193 |
| work_keys_str_mv | AT rizvinaiyer tumorresponsefromdurvalumabmedi4736tremelimumabtreatmentinpatientswithadvancednonsmallcelllungcancernsclcisobservedregardlessofpdl1status AT chaftjamie tumorresponsefromdurvalumabmedi4736tremelimumabtreatmentinpatientswithadvancednonsmallcelllungcancernsclcisobservedregardlessofpdl1status AT balmanoukianani tumorresponsefromdurvalumabmedi4736tremelimumabtreatmentinpatientswithadvancednonsmallcelllungcancernsclcisobservedregardlessofpdl1status AT goldbergsarahb tumorresponsefromdurvalumabmedi4736tremelimumabtreatmentinpatientswithadvancednonsmallcelllungcancernsclcisobservedregardlessofpdl1status AT sanbornrachele tumorresponsefromdurvalumabmedi4736tremelimumabtreatmentinpatientswithadvancednonsmallcelllungcancernsclcisobservedregardlessofpdl1status AT steelekeithe tumorresponsefromdurvalumabmedi4736tremelimumabtreatmentinpatientswithadvancednonsmallcelllungcancernsclcisobservedregardlessofpdl1status AT rebelattomarlonc tumorresponsefromdurvalumabmedi4736tremelimumabtreatmentinpatientswithadvancednonsmallcelllungcancernsclcisobservedregardlessofpdl1status AT guyu tumorresponsefromdurvalumabmedi4736tremelimumabtreatmentinpatientswithadvancednonsmallcelllungcancernsclcisobservedregardlessofpdl1status AT karakunneljoysonj tumorresponsefromdurvalumabmedi4736tremelimumabtreatmentinpatientswithadvancednonsmallcelllungcancernsclcisobservedregardlessofpdl1status AT antoniascott tumorresponsefromdurvalumabmedi4736tremelimumabtreatmentinpatientswithadvancednonsmallcelllungcancernsclcisobservedregardlessofpdl1status |